ADZE1.C
Metastatic Melanoma
Key Facts
About Adze Biotechnology
Adze Biotechnology is a private, clinical-stage company leveraging a novel oncolytic viral backbone to create targeted immunotherapies. Its lead candidate, ADZE1.C, is in Phase 1 for metastatic melanoma, with a platform capable of systemic delivery and payload-carrying to enhance checkpoint inhibitor efficacy. Founded in 2019 and based in San Francisco, the company has raised a Series A and is advancing a pipeline focused on overcoming key limitations in current cancer immunotherapy.
View full company profileAbout Adze Biotechnology
Adze Biotechnology is a private, clinical-stage company leveraging a novel oncolytic viral backbone to create targeted immunotherapies. Its lead candidate, ADZE1.C, is in Phase 1 for metastatic melanoma, with a platform capable of systemic delivery and payload-carrying to enhance checkpoint inhibitor efficacy. Founded in 2019 and based in San Francisco, the company has raised a Series A and is advancing a pipeline focused on overcoming key limitations in current cancer immunotherapy.
View full company profileTherapeutic Areas
Other Metastatic Melanoma Drugs
| Drug | Company | Phase |
|---|---|---|
| Supercarrier Prodrug | Temprian Oncology | Pre-clinical |
| EVX-01 | Evaxion | Phase 2 |
| Opdualag (nivo + relatlimab) | Ono Pharmaceutical | Approved |
| APG-115 (Alrizomadlin) | Ascentage Pharma Group | Phase 2 |